|Public (LSE: VEC)|
|Bruno Angelici, Non-Executive Chairman
Christopher Blackwell, Chief Executive Officer
Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases.
Vectura has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has disclosed development collaborations and licensed to major pharmaceutical companies. Vectura has disclosed development collaborations and license agreements with several pharmaceutical and biotechnology companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols and Tianjin KingYork Group Company Limited.
Vectura seeks to develop certain programmes itself where this will optimise value. Vectura’s formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura’s business strategy.
Vectura is based in the UK, with headquarters in Chippenham, Wiltshire and operates in Cambridge (UK) and Germany and a US operations office near Boston MA.
For further information, please visit Vectura's website at www.vectura.com